The 68Ga-PSMA PET/CT has a high clinical impact for preoperative staging, restaging biochemical recurrence after radical prostatectomy, and treatment monitoring. Dr. Chen highlights the details of this trial with two objectives. They assessed 68 Ga-PSMA PET/CT in primary prostate cancer with different clinical risks and further studied the inclusion of 11 C-Acetate PET/CT to see if there was an incremental value over 68Ga-PSMA PET CT in any of the risk-stratified groups.

Biography:

Sirong Chen, MD, Department of Nuclear Medicine & PET, Hong Kong Sanatorium & Hospital, Village Road, Happy Valley, Hong Kong, Hong Kong